skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
This white paper from Datamonitor Healthcare identifies and discusses key highlights from the 55th annual meeting of the American Society of Hematology (ASH), giving you greater insight and analysis from the conference.

Highlights from this whitepaper include:

  • CLL11 trial demonstrates superiority of Rituxan’s glycoengineered successor
  • Revlimid shows a significant clinical benefit in newly diagnosed multiple myeloma patient
  • Idelalisib proves an effective therapy for relapsed or refractory chronic lymphocytic leukemia
ASH Whitepaper

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: